Source comparison
PT-141 Be Cycled Like Other Research Compounds: Comparison Table
PT-141 (bremelanotide) MC4R agonist. Melanocortin pathway activation Prevent use-dependent receptor internalization Dose taper with 96–120 hour intervals, 10–14 day washout every 4–5 administrations 10–14 days for full MC4R membrane recycling Receptor internal
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R agonist. Melanocortin pathway activation
- Prevent use-dependent receptor internalization
- Dose taper with 96–120 hour intervals, 10–14 day washout every 4–5 administrations
- 10–14 days for full MC4R membrane recycling
- Receptor internalization accelerates with repeat dosing; block cycling compounds desensitization
- GLP-1 agonists (semaglutide, tirzepatide)
- Incretin receptor agonist. Insulin secretion and gastric emptying
- Maintain receptor sensitivity, avoid tolerance
- Not typically cycled. Therapeutic use is continuous; research protocols may use 8–12 week blocks
- 4–6 weeks for receptor re-sensitization if discontinued
- Long half-life allows steady-state dosing; PT-141's short half-life requires different timing
- GHRP-2 / GHRP-6
- Ghrelin receptor agonist. GH pulse stimulation
- Reset hypothalamic feedback suppression
- 4–6 weeks on, 2–4 weeks off
- 2–4 weeks to restore endogenous GH pulsatility
- Negative feedback cycling works; melanocortin receptors don't use feedback. They use trafficking
- BPC-157
- Tissue repair signaling (mechanism not fully characterized)
- Prevent adaptive downregulation of repair pathways
- 4–8 weeks on, 2–4 weeks off
- 2–3 weeks
- Short half-life but doesn't exhibit receptor internalization; continuous dosing is common
- CJC-1295 (with DAC)
- GHRH analog. Sustained GH release
- Avoid somatostatin rebound suppression
- 8–12 weeks on, 4–6 weeks off
- 4–6 weeks for pituitary recovery
- Long half-life enables less frequent dosing; PT-141 clears in hours but receptors stay internalized for days